Board meeting is scheduled for 26th May 2026.

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.2%Reaction day

₹910.00

prior close

₹925.45

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.4%+6.6% vs market

Pharmaceuticals peers, median of 159sector-0.7%+5.9% vs sector

On the reaction day the stock moved 6.6 pts more than Nifty Microcap 250 and 5.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.8

10m

-3.9

15m

-3.6

30m

-2.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.2-1.4+6.6-0.7+5.9

Next day

+10.5-0.9+11.4+0.0+10.5

+14.7-0.3+15.1+0.2+14.5

+12.6+0.8+11.9+1.1+11.5

+18.9+0.9+18.0+0.3+18.6

+24.9+2.5+22.4+1.1+23.8

+34.0+3.1+30.8+1.7+32.2

15d

+77.0+3.5+73.5+1.1+75.9

+89.3+8.0+81.4+2.6+86.8

+84.9+9.3+75.6+8.0+76.9

+101.2+14.0+87.2+8.1+93.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venus Remedies Ltd has scheduled a Board meeting on 26th May 2026 to consider and approve the Audited Standalone and Consolidated Financial Results for Q4 and the year ended 31st March 2026. The meeting will also consider recommending a final dividend for FY2025-26 and matters relating to the ensuing Annual General Meeting. A trading window closure is in effect from 1st April 2026 until 48 hours after the financial results are declared. This is a standard quarterly/annual results announcement with no specific financial metrics or performance indicators disclosed.

Likely market impact

This is a routine procedural announcement. Shareholders should note the trading window closure and await the actual financial results for any material impact assessment. The dividend recommendation, if approved, would be a positive signal for investors.

By the numbersConsolidated · Q4 FY26 vs Q4 FY25

	Q4 FY26	Q4 FY25	Change
Revenue	₹259.4 Cr	₹195.0 Cr	+33.0%
Operating profit	₹56.65 Cr	₹24.28 Cr	+133.3%
Profit after tax	₹47.49 Cr	₹21.00 Cr	+126.1%
EBITDA margin	24.4%	14.9%	+9.6 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.